Solid biosciences inc. (SLDB)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16
Cash flows from operating activities:
Net loss

-117,223

-74,798

-53,178

-23,773

Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of (discount)/premium on available-for-sale securities

279

90

-206

-505

Equity-based compensation expense

14,207

5,955

5,330

1,470

Depreciation expense

2,824

1,566

448

56

Loss on sale of property and equipment

-2

-4

-

-

(Gain) from revaluation of preferred unit tranche right

-

-

-459

-1,163

Changes in operating assets and liabilities:
Proceeds from landlord lease incentive for tenant improvements

-

-823

-

-

Prepaid expenses and other current and non-current assets

-4,486

4,930

-815

2,005

Accounts payable

3,779

-1,610

1,579

2,213

Accrued expenses and other current and non-current liabilities

-510

2,883

2,035

2,577

Net cash used in operating activities

-92,714

-70,197

-43,224

-20,120

Cash flows from investing activities:
Purchases of property and equipment

4,387

7,776

2,276

392

Proceeds from sale and maturities of available-for-sale securities

-60,399

-25,335

-31,621

-22,035

Purchases of available-for-sale securities

31,496

44,321

18,897

25,695

Net cash provided by (used in) investing activities

24,516

-26,762

10,448

-4,052

Cash flows from financing activities:
Payment of offering costs

2,102

2,168

2,424

-

Proceeds from issuance of common stock

49,325

-

-

-

Proceeds from issuance of pre-funded warrants

10,652

-

-

-

Proceeds from issuance of redeemable preferred units

-

-

-

3,420

Proceeds from initial public offering of common stock, net of commissions and underwriting discounts

-

133,688

-

-

Principal payments under capital lease obligation

-

13

-

-

Net cash provided by financing activities

57,875

131,507

77,078

3,420

Net decrease in cash, cash equivalents and restricted cash

-10,323

34,548

44,302

-20,752

Supplemental disclosure of non-cash investing and financing activities:
Reclassification of preferred unit tranche liability to preferred units upon settlement

-

-

-

10,841

Accretion of preferred units to redemption value

-

-

959

-4,309

Redemption of preferred units

-

-

15,685

-

Redemption of redeemable interest from non-controlling interest in Solid GT

-

-

1,925

-

Deferred offering costs included in accounts payable and accrued expenses

-

-

682

47

Property and equipment included in accounts payable and accruals

490

952

265

116

Property and equipment acquired through a capital lease

-

1,023

-

-

Series D Common Units in Exchange for Series A Common Units [Member]
Equity-based compensation expense

13

54

48

-

Issuance of units

-

-

638

-

Series 1 Senior Preferred Units [Member]
Proceeds from issuance of preferred units

-

-

24,500

-

Conversion of units into shares of common stock

-

25,000

-

-

Series 2 Senior Preferred Units [Member]
Proceeds from issuance of preferred units

-

-

55,002

-

Conversion of units into shares of common stock

-

55,002

-

-

Junior Preferred Units [Member]
Conversion of units into shares of common stock

-

44,177

-

-

Series A, B, C and D Common Units [Member]
Conversion of units into shares of common stock

-

65,180

-

-

Junior Preferred Units Upon Redemption of Class D Non-controlling Interest in Solid GT [Member]
Issuance of units

-

-

44,177

-

Series A Common Units in Exchange for Redeemable Preferred Units [Member]
Issuance of units

-

-

55,964

-

Series C Common Units in Exchange for Class B Non-controlling Interest in Solid GT [Member]
Issuance of units

-

-

2,053

-

Series D Common Units in Exchange for Class C Non-controlling Interest in Solid GT [Member]
Issuance of units

-

-

1,409

-